Cross-sectional observational study to assess the impact of chronic urticaria from the patient's perspective. CHRONIC URTICARIA ATLAS SURVEY
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: NOVARTIS FARMACEUTICA, SA
- Execution start: 27/05/2021
- End of execution: 30/11/2021
- PI: RICARDO RUIZ VILLAVERDE